Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PPP1R10_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PPP1R10_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PPP1R10_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PPP1R10_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PPP1R10_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PPP1R10_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PPP1R10_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PPP1R10_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00000756 | Thyroid | PTC | cell cycle checkpoint | 72/5968 | 169/18723 | 2.09e-03 | 1.11e-02 | 72 |
GO:00000777 | Thyroid | PTC | DNA damage checkpoint | 50/5968 | 115/18723 | 5.79e-03 | 2.61e-02 | 50 |
GO:00447736 | Thyroid | PTC | mitotic DNA damage checkpoint | 37/5968 | 81/18723 | 6.35e-03 | 2.79e-02 | 37 |
GO:00447746 | Thyroid | PTC | mitotic DNA integrity checkpoint | 38/5968 | 85/18723 | 8.78e-03 | 3.66e-02 | 38 |
GO:007259429 | Thyroid | ATC | establishment of protein localization to organelle | 247/6293 | 422/18723 | 2.88e-26 | 1.40e-23 | 247 |
GO:003450423 | Thyroid | ATC | protein localization to nucleus | 175/6293 | 290/18723 | 6.23e-21 | 1.23e-18 | 175 |
GO:000691326 | Thyroid | ATC | nucleocytoplasmic transport | 180/6293 | 301/18723 | 6.97e-21 | 1.30e-18 | 180 |
GO:005116926 | Thyroid | ATC | nuclear transport | 180/6293 | 301/18723 | 6.97e-21 | 1.30e-18 | 180 |
GO:003304423 | Thyroid | ATC | regulation of chromosome organization | 119/6293 | 187/18723 | 3.55e-17 | 3.40e-15 | 119 |
GO:000734622 | Thyroid | ATC | regulation of mitotic cell cycle | 236/6293 | 457/18723 | 7.58e-16 | 5.92e-14 | 236 |
GO:005105219 | Thyroid | ATC | regulation of DNA metabolic process | 183/6293 | 359/18723 | 5.97e-12 | 2.30e-10 | 183 |
GO:200102026 | Thyroid | ATC | regulation of response to DNA damage stimulus | 121/6293 | 219/18723 | 3.22e-11 | 1.08e-09 | 121 |
GO:004578719 | Thyroid | ATC | positive regulation of cell cycle | 158/6293 | 313/18723 | 4.18e-10 | 1.14e-08 | 158 |
GO:003220423 | Thyroid | ATC | regulation of telomere maintenance | 54/6293 | 80/18723 | 5.87e-10 | 1.56e-08 | 54 |
GO:190198715 | Thyroid | ATC | regulation of cell cycle phase transition | 187/6293 | 390/18723 | 2.36e-09 | 5.61e-08 | 187 |
GO:001703822 | Thyroid | ATC | protein import | 110/6293 | 206/18723 | 3.49e-09 | 8.09e-08 | 110 |
GO:0051054110 | Thyroid | ATC | positive regulation of DNA metabolic process | 107/6293 | 201/18723 | 7.10e-09 | 1.54e-07 | 107 |
GO:000072324 | Thyroid | ATC | telomere maintenance | 76/6293 | 131/18723 | 8.21e-09 | 1.75e-07 | 76 |
GO:004578614 | Thyroid | ATC | negative regulation of cell cycle | 181/6293 | 385/18723 | 2.64e-08 | 5.07e-07 | 181 |
GO:005117018 | Thyroid | ATC | import into nucleus | 86/6293 | 159/18723 | 8.02e-08 | 1.40e-06 | 86 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP1R10 | SNV | Missense_Mutation | novel | c.2333N>A | p.Gly778Glu | p.G778E | Q96QC0 | protein_coding | tolerated_low_confidence(0.06) | benign(0.017) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PPP1R10 | SNV | Missense_Mutation | novel | c.1669G>A | p.Val557Ile | p.V557I | Q96QC0 | protein_coding | tolerated(0.21) | probably_damaging(0.967) | TCGA-E2-A150-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PPP1R10 | SNV | Missense_Mutation | novel | c.2368N>C | p.Ser790Arg | p.S790R | Q96QC0 | protein_coding | tolerated_low_confidence(0.1) | benign(0.003) | TCGA-LL-A5YN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
PPP1R10 | insertion | Frame_Shift_Ins | novel | c.1483_1484insT | p.Gln495LeufsTer12 | p.Q495Lfs*12 | Q96QC0 | protein_coding | | | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
PPP1R10 | insertion | Nonsense_Mutation | novel | c.2107_2108insGAGGTTAGAACTGACTACAAAGACACAGGAA | p.Tyr703Ter | p.Y703* | Q96QC0 | protein_coding | | | TCGA-AQ-A54N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPP1R10 | SNV | Missense_Mutation | rs748839668 | c.2764C>T | p.Arg922Cys | p.R922C | Q96QC0 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.984) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PPP1R10 | SNV | Missense_Mutation | rs774652564 | c.2345G>A | p.Arg782His | p.R782H | Q96QC0 | protein_coding | deleterious_low_confidence(0.01) | benign(0.12) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PPP1R10 | SNV | Missense_Mutation | rs767544705 | c.1343G>A | p.Arg448Gln | p.R448Q | Q96QC0 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PPP1R10 | SNV | Missense_Mutation | rs747071643 | c.2255N>A | p.Arg752His | p.R752H | Q96QC0 | protein_coding | tolerated_low_confidence(0.08) | benign(0.057) | TCGA-DR-A0ZL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PPP1R10 | SNV | Missense_Mutation | novel | c.249N>C | p.Lys83Asn | p.K83N | Q96QC0 | protein_coding | deleterious(0.02) | possibly_damaging(0.863) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |